Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin for acute traumatic cervical spinal cord injury
IRCT20180923041103N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Dec 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of erythropoietin and methylprednisolone in acute cervical spinal cord injury (ACSCI) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: American Spinal Injury Association score, mortality and 1 more. Started Dec 2015; status: completed.
02
Drugs
erythropoietinmethylprednisolone
03
Conditions
acute cervical spinal cord injury (ACSCI)
Beyond the preview
Go deeper on IRCT20180923041103N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180923041103N1.